173 related articles for article (PubMed ID: 26699831)
1. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
2. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation.
Ludwig MS; Kuban DA; Strom SS; Du XL; Lopez DS; Yamal JM
BMC Cancer; 2015 Mar; 15():190. PubMed ID: 25885406
[TBL] [Abstract][Full Text] [Related]
3. The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
Onal C; Guler OC; Erbay G; Elmali A
Prostate; 2024 Jun; 84(8):763-771. PubMed ID: 38528236
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma TM; Sun Y; Malone S; Roach M; Dearnaley D; Pisansky TM; Feng FY; Sandler HM; Efstathiou JA; Syndikus I; Hall EC; Tree AC; Sydes MR; Cruickshank C; Roy S; Bolla M; Maingon P; De Reijke T; Nabid A; Carrier N; Souhami L; Zapatero A; Guerrero A; Alvarez A; Gonzalez San-Segundo C; Maldonado X; Romero T; Steinberg ML; Valle LF; Rettig MB; Nickols NG; Shoag JE; Reiter RE; Zaorsky NG; Jia AY; Garcia JA; Spratt DE; Kishan AU;
J Clin Oncol; 2023 Feb; 41(4):881-892. PubMed ID: 36269935
[TBL] [Abstract][Full Text] [Related]
5. Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.
Andruska N; Fischer-Valuck BW; Agabalogun T; Carmona R; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Baumann BC
Clin Genitourin Cancer; 2022 Apr; 20(2):123-131. PubMed ID: 35086762
[TBL] [Abstract][Full Text] [Related]
6. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
Mell LK; Pugh SL; Jones CU; Nelson TJ; Zakeri K; Rose BS; Zeitzer KL; Gore EM; Bahary JP; Souhami L; Michalski JM; Hartford AC; Mishra MV; Roach M; Parliament MB; Choi KN; Pisansky TM; Husain SM; Malone SC; Horwitz EM; Feng F
Eur Urol; 2024 Apr; 85(4):373-381. PubMed ID: 36710205
[TBL] [Abstract][Full Text] [Related]
7. Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy.
Beasley M; Williams SG; Pickles T;
Radiat Oncol; 2008 Apr; 3():8. PubMed ID: 18423030
[TBL] [Abstract][Full Text] [Related]
8. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.
Nguyen PL; Martin NE; Choeurng V; Palmer-Aronsten B; Kolisnik T; Beard CJ; Orio PF; Nezolosky MD; Chen YW; Shin H; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):186-192. PubMed ID: 28117383
[TBL] [Abstract][Full Text] [Related]
9. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Outcomes in Patients With Clinically Lymph Node Positive Prostate Cancer After Definitive Radiotherapy.
Kim TH; Kim DY; Kim JS
In Vivo; 2023; 37(5):2365-2370. PubMed ID: 37652494
[TBL] [Abstract][Full Text] [Related]
11. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
Heesterman BL; Aben KKH; van den Bergh ACM; van der Voort van Zyp JRN; Bokhorst LP
Urol Oncol; 2024 May; ():. PubMed ID: 38724349
[TBL] [Abstract][Full Text] [Related]
12. Decision Regret and Bother With the Addition of Androgen Deprivation Therapy to Definitive Radiation Treatment for Localized Prostate Cancer.
Booth V; Eade T; Hruby G; Lieng H; Brown C; Guo L; Dhillon H; Kneebone A
Pract Radiat Oncol; 2023; 13(5):e400-e408. PubMed ID: 37169149
[TBL] [Abstract][Full Text] [Related]
13. Long-term Overall Survival after External Beam Radiotherapy for Localised Prostate Cancer.
Jahreiβ MC; Incrocci L; Dirkx M; de Vries KC; Aben KKH; Bangma C; Heemsbergen WD
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e689-e698. PubMed ID: 37852813
[TBL] [Abstract][Full Text] [Related]
14. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
Roy S; Romero T; Michalski JM; Feng FY; Efstathiou JA; Lawton CAF; Bolla M; Maingon P; de Reijke T; Joseph D; Ong WL; Sydes MR; Dearnaley DP; Tree AC; Carrier N; Nabid A; Souhami L; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Reiter RE; Rettig MB; Nickols NG; Steinberg ML; Valle LF; Ma TM; Farrell MJ; Neilsen BK; Juarez JE; Deng J; Vangala S; Avril N; Jia AY; Zaorsky NG; Sun Y; Spratt D; Kishan AU;
J Clin Oncol; 2023 Nov; 41(32):5005-5014. PubMed ID: 37639648
[TBL] [Abstract][Full Text] [Related]
15. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer.
Nikitas J; Kishan A; Chang A; Duriseti S; Nichols NG; Reiter R; Rettig M; Brisbane W; Steinberg ML; Valle L
World J Urol; 2024 Mar; 42(1):165. PubMed ID: 38492111
[TBL] [Abstract][Full Text] [Related]
16. Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer.
Ni X; Luu M; Ma W; Zhang T; Wei Y; Freedland SJ; Ye D; Daskivich TJ; Zhu Y
J Natl Compr Canc Netw; 2023 Jul; 21(7):733-741.e3. PubMed ID: 37433430
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation alone versus combined with pelvic radiation for adverse events and quality of life in clinically node-positive prostate cancer.
Lee TH; Pyo H; Yoo GS; Kim JH; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Park W
Sci Rep; 2024 Apr; 14(1):8207. PubMed ID: 38589463
[TBL] [Abstract][Full Text] [Related]
18. Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.
Amini A; Kavanagh BD; Rusthoven CG
Ann Transl Med; 2016 Jan; 4(1):14. PubMed ID: 26855950
[TBL] [Abstract][Full Text] [Related]
19. Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D'Amico Intermediate-/High-Risk Prostate Cancer in Older Patients.
Couderc AL; Nicolas E; Boissier R; Boucekine M; Bastide C; Badinand D; Rossi D; Mugnier B; Villani P; Karsenty G; Cowen D; Lechevallier E; Muracciole X
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33383957
[TBL] [Abstract][Full Text] [Related]
20. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
